DNM1L and melanoma: We also found that a pharmacological inhibitor of DRP-1, called Mdivi-153,54, enhanced the cytotoxic effect of the A-1210477 plus ABT-263 combination treatment in multiple melanoma cells lines (Fig. 8b).